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Abstract: Despite the worldwide extent of methamphetamine dependence, no medication 
has been shown to effectively treat afflicted individuals. One relatively unexplored approach 
is modulation of cholinergic system function. Animal research suggests that enhancement of 
central cholinergic activity, possibly at nicotinic acetylcholine receptors (nAChRs), can reduce 
methamphetamine-related behaviors. Further, preliminary findings indicate that rivastigmine, 
a cholinesterase inhibitor, may reduce craving for methamphetamine after administration of the 
drug in human subjects. We therefore performed a double-blind, placebo-controlled, crossover 
pilot study of the safety and tolerability of varenicline in eight methamphetamine-dependent 
research subjects. Varenicline is used clinically to aid smoking cessation, and acts as a partial 
agonist at α4b2 nAChRs with full agonist properties at α7 nAChRs. Oral varenicline dose was 
titrated over one week to reach 1 mg twice daily, and then was co-administered with 30 mg 
methamphetamine, delivered in 10 intravenous (iv) infusions of 3 mg each. Varenicline was 
found to be safe in combination with iv methamphetamine, producing no cardiac rhythm 
disturbances or alterations in vital sign parameters. No adverse neuropsychiatric sequelae were 
detected either during varenicline titration or following administration of methamphetamine. 
The results suggest that varenicline warrants further investigation as a potential treatment for 
methamphetamine dependence.
Keywords: varenicline, methamphetamine, treatment, safety, nicotinic, acetylcholine
Introduction
Methamphetamine (MA) abuse is a global public health problem with a large 
public health impact.1 In 2008, it was estimated that there were 100,000–200,000 
MA-dependent individuals in the United States.2 Nonetheless, no medications are 
approved for the treatment of MA dependence.3
Studies in animal models suggest that enhancement of central cholinergic 
activity, possibly at nicotinic acetylcholine receptors (nAChRs), can reduce 
MA-related behaviors. For example, administration of either nicotine or donepezil, 
a cholinesterase inhibitor, reduced reinstatement induced by exposure to MA-related 
cues and by administration of priming doses of MA rats.4 In addition, administra-
tion of the alkaloid lobeline, which has high affinity for nicotinic acetylcholine 
receptors (nAChRs) and also inhibits the function of vesicular monoamine and 
dopamine transporters, can reduce behavioral and biochemical markers of addiction 
in rodent models of stimulant dependence.5–7 Lastly, preliminary findings indicate 
that rivastigmine, a cholinesterase inhibitor, may reduce positive subjective effects 
of MA in human subjects.8
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On the basis of these findings, we hypothesized that 
varenicline, which is used clinically as a treatment for 
smoking cessation and is a partial agonist at α4b2 nAChRs 
and a full agonist at α7 nAChRs,9 may be a useful treatment 
for MA dependence. The purpose of this pilot study was 
to evaluate the safety and tolerability of varenicline when 
co-administered with MA.
Methods
subjects
Twelve nontreatment-seeking MA-dependent research par-
ticipants were enrolled in this research study after receiv-
ing a detailed explanation of the study and giving written 
informed consent as approved by the UCLA Institutional 
Review Board.
Participants were excluded if they had major medical 
illness as determined by medical history, physical examina-
tion, screening electrocardiogram (EKG), and laboratory 
assay. The Structured Clinical Interview for DSM-IV Axis I 
Disorders (SCID-I) was administered to establish MA depen-
dence (inclusion criterion) and to exclude those participants 
who met criteria for other current Axis I diagnoses (includ-
ing dependence on other drugs of abuse or alcohol) other 
than nicotine or marijuana dependence. Any history of 
recent psychotropic medication use was exclusionary. The 
participants selected were active tobacco smokers and had 
recently used MA (as assessed via urine test) at screening. 
Participants resided at the UCLA General Clinical Research 
Center (GCRC) for the duration of the study (18 days divided 
into two phases; see below), and were monitored via daily 
urine and alcohol breath testing to confirm abstinence from 
alcohol, MA, opiates, cannabinoids, PCP, and cocaine. Par-
ticipants were asked to abstain from MA for at least four 
days before admission to inpatient phases of the study, and 
were required to have an MA-free urine drug screen prior 
to both admissions. All participants were compensated for 
their participation.
study design
The study was conducted on an inpatient basis in two 
crossover phases of varenicline or placebo administration, 
separated by a two- to four-week washout period. In phase I, 
qualified participants were tested with 30 mg intravenous 
(iv) MA (over 2.5 hours) on day 1 prior to initiating study 
medication, to exclude any who might have an exagger-
ated response to iv MA alone. Given tolerability of IV MA 
administration, on day 3 in the evening, participants were 
given the first dose of the first test compound condition 
(0.5 mg varenicline or placebo). They received this treatment 
once in the evening for two days, then twice daily for two 
days, then a double dose (ie, 1.0 mg varenicline or placebo) 
twice daily for three days, and then a final dose (1.0 mg 
varenicline or placebo) on the morning of the last day of the 
first phase (day 10). Participants were given a self-report 
questionnaire in the morning on each inpatient day to monitor 
depressive symptoms (Beck Depression Inventory [BDI]).10 
Participants were discharged from the hospital after all study 
procedures were complete on day 10.
After at least 14 days, participants returned to complete 
phase II of inpatient procedures, which were identical to 
those on days 3–10 of phase I of the study, but with the 
opposite test compound condition (varenicline or placebo), 
and were discharged again after all procedures on day 8.
Participants returned for assessment of any delayed 
adverse events on a follow-up visit at least 14 days after 
discharge from phase II of the study, after which time they 
completed the study.
MA challenge sessions
Participants received double-blinded challenge sessions 
with iv infusions of either MA or saline in the mornings 
and afternoon of days 1 and 9 of phase I, and day 7 of phase II. 
All infusion procedures were performed and monitored by 
study physicians (TZ and KM). Via a patient-controlled 
analgesia (PCA) pump, either 3 mg of MA or saline was 
infused intravenously over 2 minutes, every 15 minutes, for 
a total of 10 infusions (30 mg MA or saline over 2.5 hours). 
In the afternoons of the same study days, the challenge ses-
sions were repeated with the opposite infusion condition 
(10 infusions of 3 mg MA or saline). Participants received a 
total of 30 mg of iv MA during each challenge day. During 
challenge sessions, participants had their blood pressure and 
heart rate monitored frequently, and the EKG was evaluated 
via continuous cardiac monitoring.
Data analysis
All data were statistically analyzed as raw scores (Number 
Cruncher Statistical Systems, Kaysville, UT; SPSS Inc., 
Chicago, IL). The data obtained during challenge sessions 
included cardiovascular measures (heart rate and blood pres-
sure), which were analyzed by three-factor, repeated mea-
sures analysis of variance (ANOVA) with Test Compound 
(varenicline, placebo), Infusion (MA, saline) and Time (-15, 
5, 20, 35, 50, 65, 80, 95, 110, 125, and 140 minutes) as fac-
tors. The data were also assessed across the study duration 
on cardiovascular parameters (measured once daily) and 
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BDI using a two-factor, repeated measures ANOVA with 
Test Compound and Day (1–8) as factors. Following each 
ANOVA, Tukey–Kramer post hoc tests were conducted if a 
significant main effect or interaction was detected. The data 
from the BDI were also analyzed across study conditions by 
independent-samples t-test. The data from adverse events 
frequencies were analyzed by one-sided Fisher’s exact test. 
Effects were considered significant at P  0.05.
Results
Demographics
Of the 12 enrolled participants, eight subjects completed both 
phases of the study (six males, two females; see Table 1). 
Three subjects voluntarily withdrew from the study due to 
personal reasons, and one was excluded before initiating 
study procedures due to positive urine drug testing after 
admission. Six of the completing subjects were Caucasian, 
one was Hispanic, and one was African–American.
Adverse events (AEs)
No serious adverse events were reported during the study. 
Six participants reported at least one mild AE when they 
received placebo, and seven participants reported at least 
one mild AE when they received varenicline (see Table 2 
for AEs). Of the 12 enrolled participants, 11 took part in at 
least one Test Compound condition. Of the three subjects 
who discontinued the study for personal reasons, two were 
receiving placebo and one was receiving varenicline. The most 
commonly reported AE was insomnia: six participants sporadi-
cally reported insomnia during varenicline maintenance, and 
six participants sporadically reported insomnia during placebo 
maintenance. The BDI score of only one participant exceeded 
15 during varenicline dose titration. Other infrequently reported 
AEs were headache, nausea, diarrhea and constipation. Fisher’s 
exact test, performed to compare the frequencies of reported 
study condition-related adverse events between the varenicline 
and placebo conditions, revealed no overall differences.
cardiovascular measures
The three-factor, repeated-measures ANOVA revealed a 
significant main effect of Time and interaction of Time × 
Infusions on systolic pressure (Table 3). Post hoc analyses 
indicated that MA infusions significantly increased systolic 
pressure at several time points (35, 65, 80, 95, 110, 125, and 
140 minutes) relative to that at -15 minutes, regardless of 
varenicline or placebo administration. Saline infusions did not 
significantly alter systolic pressure across time, regardless of 
varenicline or placebo administration (Figure 1, top panel).
For diastolic pressure, the three-factor repeated-measure 
ANOVA revealed a significant main effect of Time, interac-
tion of Time × Infusions and interaction of Time × Infusions × 
Test Compound (Table 3). Post hoc analyses indicated that 
Table 1 Demographic characteristics
Mean (SD)
Age (years) 39.3 (5.8)
Education (years) 12.5 (2.0)
Body mass index 24.6 (3.4)
cigarettes smoked
 Per day 13.4 (8.3)
 number of years 16.6 (10.2)
Alcoholic drinks consumed
 Per week 1.2 (1.4)
 number of years 13.7 (6.9)
MA use
 number of days in the past 30 days 22.9 (9.7)
 number of years 15.3 (8.8)
Marijuana use
 number of days in the past 30 days 5.3 (11.2)
 number of years 10.8 (13.5)
cocaine use
 number of days in the past 30 days 0.0 (0.0)
 number of years 1.9 (3.4)
Opioids use
 number of days in the past 30 days 0.0 (0.0)
 number of years 2.4 (6.0)
hallucinogen use
 number of days in the past 30 days 0.0 (0.0)
 number of years 1.8 (1.8)
sedatives use
 number of days in the past 30 days 0.0 (0.0)
 number of years 0.6 (0.9)
Notes:  The demographic data are expressed as mean values for eight participants. 
The bracketed values indicate standard deviation.
Table 2 summary of adverse events
Adverse events Varenicline Placebo p
insomnia 67% 55% 0.47
headache 33% 9% 0.22
nausea 11% 9% 0.71
Depressed mood;  
BDi  15
11% 0% 0.45
constipation 0% 18% 0.29
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MA significantly increased diastolic pressure at several time 
points (65, 80, 95, 110, 125, and 140 minutes) relative to that 
at -15 minutes. Saline infusions did not significantly alter dia-
stolic pressure across time. Varenicline did not significantly 
modify MA-induced enhancement in diastolic pressure across 
time. Although there was a trend for varenicline to reduce 
baseline diastolic pressure across time relative to that observed 
after placebo (see Figure 1, middle panel, open and closed 
circles), the trend did not achieve statistical significance.
For heart rate, the three-factor, repeated measures 
ANOVA revealed a significant main effect of Time, interac-
tion of  Time × Infusions and interaction of Infusions × Study 
Drug (Table 3). Post hoc analyses indicated that MA signifi-
cantly increased heart rate at several time points (65, 80, 95, 
110, 125, and 140 minutes) relative to that at -15 minutes, 
regardless of varenicline or placebo administration. Saline 
infusions did not significantly alter heart rate across time, 
regardless of varenicline or placebo administration. Vareni-
cline did not significantly modify MA-induced enhancement 
in heart rate across time. Although there was a trend for 
varenicline to reduce baseline heart rate relative to placebo 
(Figure 1, bottom panel, open and closed circles), the trend 
did not achieve statistical significance.
Considering changes in cardiovascular effects over the 
course of the study, the two-factor repeated-measure ANOVA 
did not reveal significant effects of Day, Test Compound, 
or interaction on systolic pressure, diastolic pressure, and 
heart rate (Table 3). The daily administration of varenicline 
or placebo did not affect cardiovascular parameters across 
days.
Depressive symptoms
The two-factor, repeated measures ANOVA did not reveal a 
significant main effect of Test Compound, Day and interaction 
of Test Compound × Day (Table 3) on BDI scores. Because 
varenicline did not significantly affect depressive symptoms 
across days, the data were combined across days, and pre-
sented as a function of Test Compound in Figure 2. There 
was no significant difference in the average BDI reported by 
participants across study conditions (Figure 2). No suicidal 
thoughts were recorded by any participant at any time during 
the study.
Discussion
Varenicline (2 mg daily dose) was well tolerated in the MA-
dependent participants who also were cigarette smokers, and 
had been pre-screened to exclude individuals with substantial 
medical or psychiatric co-morbidities. No significant dif-
ferences were observed between the effects of varenicline 
and placebo in terms of overall adverse events, depressive 
symptoms, or cardiovascular parameters. Moreover, there 
was no association between the varenicline treatment and 
propensity to discontinue the study. Therefore, the present 
data are consistent with the previously documented safety 
and tolerability of varenicline treatment in healthy tobacco-
dependent subjects with no pre-existing psychiatric or medical 
conditions.9,11–13
While randomized controlled trials have shown vareni-
cline to be safe and well-tolerated in healthy participants, 
many case reports of neuropsychiatric disturbances coincident 
with varenicline treatment have been published recently.14 
Post-marketing surveillance by the US Food and Drug 
Administration has led to the issuance of a “black box warn-
ing” about the potential for “serious neuropsychiatric symp-
toms” for varenicline in July of 2009.15 These concerns have 
also been addressed by two recent retrospective studies.16,17 
In a cohort study of 2700 patients taking varenicline, two 
suicide attempts were noted in patients with pre-existing 
Table 3 summary of F statistics
Test 
compound 
(df1,7)
Infusion 
(df1,7)
Time (df10,70) Test  
compound × 
Infusion  
(df1,7)
Test  
Compound × 
Time  
(df10,70)
Infusion × 
Time (df10,70)
Test compound × 
Infusion × Time  
(df10,70)
cardiovascular 
measures
systolic pressure 0.2 3.23 2.06 1.1 0.54 11.39 1.46
Diastolic pressure 1.25 0.3 2.83 2.5 0.82 5.34 3.39
heart rate 0.27 0.85 5.07 7.56 1.67 7.09 0.28
Test 
compound 
(df1,7)
Day (df7,49) Test  
compound × Day 
(df7,49)
Beck depression  
inventory (BDi)
2.10 1.35 1.00
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Figure 1 Time-course of effects of methamphetamine (MA) and saline during 
varenicline or placebo maintenance on systolic pressure (top panel), diastolic pressure 
(middle panel) and heart rate (bottom panel).
Notes: The data collected during infusion sessions in phase i (day 9) and phase ii (day 7) 
are shown. X-axis: Time in min, relative to the first MA infusion. Data are expressed as mean 
of eight participants. Unidirectional brackets indicate one standard error of mean.
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Figure 2 Average BDi scores across study conditions during test compound admin-
istration (varenicline and placebo). BDi scores were recorded in the mornings after 
each dose of both varenicline and placebo study conditions, and were averaged across 
both study conditions and participants.
Notes: Bars represent mean of eight participants and 64 measurements for placebo, 
63 for varenicline. Unidirectional brackets indicate one standard deviation.
Abbreviation: BDi, Beck’s Depression inventory.
Taken together, these early reports provide preliminary 
evidence that varenicline treatment may be associated with 
a worsening of psychiatric symptoms in a minority of indi-
viduals with a history of psychiatric illness. However, the 
present results, combined with the findings from randomized 
controlled trials,9,11–13 suggest that varenicline is not likely to 
be associated with neuropsychiatric sequelae in individuals 
without a history of psychiatric disease.
To our knowledge, our study is the first to address the 
safety or tolerability of varenicline when co-administered with 
a stimulant in humans. Varenicline is well-absorbed orally 
irrespective of dose or presence of food, is primarily excreted 
in the urine unmetabolized, and has no documented drug–drug 
interactions.18 Therefore, there is no a priori reason that it 
should interact clinically with MA, which is primarily hepati-
cally metabolized by the cytochrome p450 system.19 Along 
with the lack of known metabolic interactions for varenicline, 
our data should provide reassurance to clinicians who may be 
concerned that patients taking varenicline may be illicitly abus-
ing stimulants, as there is not likely to be additional risk via a 
potentially harmful interaction between varenicline and MA.
There are several limitations of this pilot study, includ-
ing the small sample size although there is not even a trend 
for untoward interactions between varenicline and MA at 
the doses given. In addition, the repeated dosing with a 
low dose (3 mg) of iv MA may not allow generalization of 
these data to clinical populations of MA-dependent patients, 
who may take substantially greater doses of MA. Lastly, as 
psychiatric illness.16 In a retrospective review of 50 patients 
followed through 12 weeks of varenicline therapy, each of 
the four patients who discontinued varenicline use due to 
mood problems had pre-existing psychiatric conditions.17 
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varenicline was administered over a relatively short period 
(slightly longer than one week) the present results may not 
be representative of findings in clinical populations taking 
varenicline for longer periods of time.
Given the lack of neuropsychiatric adverse events seen 
in otherwise healthy, MA-dependent participants while 
taking varenicline, along with the safety and tolerability of 
varenicline when co-administered with iv MA, we believe 
that varenicline should continue to be tested as a possible 
candidate medication for the treatment of MA dependence. 
In this vein, other investigators have also proposed that 
varenicline may have utility for the treatment of addictive 
disorders beyond nicotine dependence.20 Overall, the present 
data suggest that varenicline warrants further investigation 
as a potential treatment for MA dependence.
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